TR201908522T4 - Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. - Google Patents
Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. Download PDFInfo
- Publication number
- TR201908522T4 TR201908522T4 TR2019/08522T TR201908522T TR201908522T4 TR 201908522 T4 TR201908522 T4 TR 201908522T4 TR 2019/08522 T TR2019/08522 T TR 2019/08522T TR 201908522 T TR201908522 T TR 201908522T TR 201908522 T4 TR201908522 T4 TR 201908522T4
- Authority
- TR
- Turkey
- Prior art keywords
- hydroxybutyrate
- compositions
- ketone
- racemic
- blood lipid
- Prior art date
Links
- 239000003524 antilipemic agent Substances 0.000 title abstract 2
- 150000002576 ketones Chemical class 0.000 title 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract 1
- PUPZLCDOIYMWBV-SCSAIBSYSA-N (R)-butane-1,3-diol Chemical compound C[C@@H](O)CCO PUPZLCDOIYMWBV-SCSAIBSYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000010030 glucose lowering effect Effects 0.000 abstract 1
- 235000015263 low fat diet Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Hastalarda serum kolesterolü ve/veya trigliserit seviyelerini düşüren bileşimler sunulmaktadır. Bileşimler rasemik ?-hidroksibütirat veya D-?-hidroksibütirat (isteğe bağlı olarak asit formunda), rasemik ?-hidroksibütirat veya D-?-hidroksibütiratın fizyolojik olarak uyumlu tuzları, D-?-hidroksibütirat esterleri, doğrusal veya siklik formda 2 ila 20 veya daha fazla monomerik birim içeren D-?-hidroksibütirat oligomerleri, rasemik 1,3-bütandiol veya R-1,3 bütandiolü tek başına içerebilir ve bir hastaya düşük yağ içerikli bir diyetle birlikte uygulanabilir. Bileşimler besin takviyeleri olarak formüle edilebilir veya a) antihipertansif; b) antienflamatuvar; c) glukoz düşürücü; veya d) antilipemik maddeler içeren terapötik bileşimlere dâhil edilebilir. Açıklanan bileşimler damar hastalığını önlemek veya tersine çevirmek için tek başlarına veya başka terapötik maddelerle birlikte de uygulanabilir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1896208P | 2008-01-04 | 2008-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201908522T4 true TR201908522T4 (tr) | 2019-07-22 |
Family
ID=40853425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/08522T TR201908522T4 (tr) | 2008-01-04 | 2009-01-05 | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
Country Status (8)
Country | Link |
---|---|
US (4) | US9211275B2 (tr) |
EP (1) | EP2240017B1 (tr) |
CN (2) | CN106038532B (tr) |
AU (1) | AU2009204370B2 (tr) |
DK (1) | DK2240017T3 (tr) |
ES (1) | ES2730879T3 (tr) |
TR (1) | TR201908522T4 (tr) |
WO (1) | WO2009089144A1 (tr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2670413T3 (es) | 2003-06-03 | 2018-05-30 | The United States Government As Represented By The Department Of Health And Human Services | Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
EP2914251B1 (en) * | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
EP2984066B1 (en) | 2013-03-14 | 2017-02-01 | Oxford University Innovation Limited | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
KR20150130312A (ko) | 2013-03-19 | 2015-11-23 | 유니버시티 오브 사우스 플로리다 | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 |
JP6655016B2 (ja) * | 2014-01-10 | 2020-02-26 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心不全のリスクを決定するための方法 |
EP3177284B1 (en) | 2014-07-21 | 2020-01-15 | Oulun Yliopisto | Oligomeric forms of 3-hydroxybutyrate |
CN104940181B (zh) * | 2015-06-29 | 2018-02-16 | 齐锦生 | β‑羟丁酸或其药学上可接受的盐的用途 |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10292952B2 (en) * | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
US20170266147A1 (en) * | 2016-03-18 | 2017-09-21 | Csilla Ari D'Agostino | Methods of increasing latency of anesthetic induction using ketone supplementation |
US12109182B2 (en) * | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
GB201616058D0 (en) * | 2016-09-21 | 2016-11-02 | Chain Biotechnology Ltd | Probiotic composition |
US20180125812A1 (en) | 2016-11-04 | 2018-05-10 | Emory University | Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer |
US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
CA3053663C (en) * | 2017-04-12 | 2021-09-07 | Franco CAVALERI | Butyrate and beta-hydroxybutyrate compositions and methods of use thereof |
CN107083406B (zh) * | 2017-05-27 | 2021-02-02 | 浙江华睿生物技术有限公司 | (r)-3-羟基丁酸的生产方法 |
GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
CN111050779A (zh) * | 2017-08-18 | 2020-04-21 | 佐藤拓己 | 血糖值尖峰抑制剂、食品及血糖值尖峰抑制剂的制造方法 |
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
AU2019282691A1 (en) * | 2018-06-05 | 2020-12-24 | Flagship Pioneering Innovations V, Inc. | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease |
GB2577723A (en) | 2018-10-04 | 2020-04-08 | Tdeltas Ltd | Compounds for new use |
WO2020167571A1 (en) * | 2019-02-11 | 2020-08-20 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
CN114025752A (zh) * | 2019-02-11 | 2022-02-08 | 阿克塞斯全球科学有限责任公司 | 富含R-对映体的非外消旋β-羟基丁酸根化合物和组合物以及使用方法 |
CN109806251A (zh) * | 2019-03-04 | 2019-05-28 | 清华大学 | 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用 |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
CN110776425B (zh) * | 2019-10-23 | 2021-02-26 | 清华大学 | 一种(r)-3-羟基丁酸及其低聚物的制备方法 |
GB201918657D0 (en) | 2019-12-17 | 2020-01-29 | Tdeltas Ltd | Compounds for new use |
CN117677383A (zh) * | 2021-07-17 | 2024-03-08 | 瑞士凯托股份公司 | 酮体或生酮化合物与镇痛剂或抗氧化剂的组合 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU507322A1 (ru) | 1973-07-26 | 1976-03-25 | Московский Научно-Исследовательский Институт Косметологии | Регул тор гормонального обмена кожи |
US3984566A (en) | 1974-02-25 | 1976-10-05 | Scott Eugene J Van | Method of alleviating the symptoms of dandruff |
IT1051853B (it) | 1975-01-07 | 1981-05-20 | Basf Ag | Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione |
US4380549A (en) | 1975-07-23 | 1983-04-19 | Scott Eugene J Van | Topical treatment of dry skin |
JPS54138126A (en) | 1978-04-17 | 1979-10-26 | Ajinomoto Co Inc | Remedy for diabetes |
EP0250559A1 (en) | 1985-12-18 | 1988-01-07 | VEECH, Richard L. | Parenteral nutrition therapy with amino acids |
JPH0755158B2 (ja) | 1986-10-30 | 1995-06-14 | チッソ株式会社 | 光学活性エステルの製造法 |
JP2579779B2 (ja) | 1987-10-08 | 1997-02-12 | 日本車輌製造株式会社 | 飼料の製造法 |
BE1001209A3 (fr) | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
JPH0383950A (ja) | 1989-08-28 | 1991-04-09 | Kanegafuchi Chem Ind Co Ltd | グリセリド誘導体およびその製造法 |
JP2873497B2 (ja) | 1990-09-03 | 1999-03-24 | 理化学研究所 | 脂質代謝調節剤 |
JP2884123B2 (ja) | 1992-01-17 | 1999-04-19 | 高砂香料工業株式会社 | 生分解性光学活性ポリマー、その中間体オリゴマー、およびそれらの製造方法 |
US5654266A (en) | 1992-02-10 | 1997-08-05 | Chen; Chung-Ho | Composition for tissues to sustain viability and biological functions in surgery and storage |
US5281691A (en) | 1992-06-19 | 1994-01-25 | Eastman Kodak Company | Poly(3-hydroxyalkanoates) |
JP3193542B2 (ja) | 1993-09-08 | 2001-07-30 | カネボウ株式会社 | 皮膚老化防止化粧料 |
WO1995009144A1 (en) | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | Nutritive water soluble glycerol esters of hydroxy butyric acid |
ATE196486T1 (de) | 1994-08-10 | 2000-10-15 | Peter Neuenschwander | Biokompatibles blockcopolymer |
US6306828B1 (en) | 1995-04-06 | 2001-10-23 | Baxter International, Inc. | Enantiomerically-enhanced nutritional energy substrates |
JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
US6126953A (en) | 1996-08-19 | 2000-10-03 | The Procter & Gamble Company | Fragrance delivery systems for personal care articles |
JPH10175855A (ja) | 1996-10-16 | 1998-06-30 | Taisho Pharmaceut Co Ltd | 肉体疲労改善剤 |
US20090253781A1 (en) | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6316038B1 (en) | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
JP4740426B2 (ja) | 1997-03-17 | 2011-08-03 | ビーティージー・インターナショナル・リミテッド | 治療用組成物 |
JPH10265378A (ja) | 1997-03-25 | 1998-10-06 | Ofutekusu:Kk | 角膜上皮損傷治療剤 |
ATE359071T1 (de) | 1997-05-15 | 2007-05-15 | Univ Washington | Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen |
US6727258B2 (en) | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
US6380244B2 (en) | 1998-07-22 | 2002-04-30 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
RU2242227C2 (ru) * | 1998-09-15 | 2004-12-20 | Би Ти Джи Интернэшнл Лимитед | Терапевтические композиции (ii) |
WO2001013877A1 (en) | 1999-08-20 | 2001-03-01 | Unilever Plc | A method for reducing skin irritation and sting from weak carboxylic acid |
EP1248849B1 (en) | 2000-01-14 | 2008-08-20 | Serono Genetics Institute S.A. | Obg3 globular head and uses thereof for decreasing body mass |
ES2323940T3 (es) | 2000-05-01 | 2009-07-28 | Accera, Inc. | Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer. |
US6753384B2 (en) | 2000-07-14 | 2004-06-22 | Metabolix, Inc. | Polyurethanes obtained from hydroxyalkanoates and isocyanates |
AUPR177300A0 (en) | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
DE20205184U1 (de) | 2002-03-27 | 2002-12-19 | Bartz, Volker, 35440 Linden | Blutfettsenker zur oralen Einnahme |
CN1483355A (zh) | 2002-09-16 | 2004-03-24 | 岚 高 | 抗疲劳饮料配方 |
WO2004105742A1 (en) | 2003-06-02 | 2004-12-09 | Isis Innovation Limited | Treatment of muscle fatigue |
ES2670413T3 (es) | 2003-06-03 | 2018-05-30 | The United States Government As Represented By The Department Of Health And Human Services | Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato |
JP2005247821A (ja) * | 2004-02-06 | 2005-09-15 | Ophtecs Corp | 炎症性サイトカインの産生を抑制するための眼科用組成物 |
DE102004007029A1 (de) | 2004-02-12 | 2005-09-08 | Consortium für elektrochemische Industrie GmbH | Verfahren zur enantioselektiven Reduktion von Ketoverbindungen durch Enzyme |
WO2006020137A2 (en) | 2004-07-16 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric compounds |
EP1778615A4 (en) * | 2004-07-20 | 2010-01-06 | Btg Int Ltd | OLIGOMERE KETONE COMPOUNDS |
EP1778212A4 (en) * | 2004-07-23 | 2010-12-08 | Btg Int Ltd | SACCHARIDES CETOGENES |
US8124063B2 (en) | 2004-10-25 | 2012-02-28 | Conopco, Inc. | Method for moisturizing human skin using dihydroxypropyltri(C1-C3 alkyl) ammonium salts |
ITTO20040918A1 (it) | 2004-12-29 | 2005-03-29 | Luigi Ambrosio | Idrogel polimerici superassorbenti biodegradabili e procedimento per la loro preparazione |
WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
ES2338704T3 (es) | 2005-11-29 | 2010-05-11 | Basf Se | Procedimiento para la transesterificacion o para la esterificacion de cadenas laterales en polimeros. |
EP2500017B1 (en) | 2006-04-03 | 2017-09-06 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
US20090239945A1 (en) | 2006-04-12 | 2009-09-24 | John Casey | Oral Composition with an Antiageing Effect on the Skin |
US7807718B2 (en) | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
JP5030553B2 (ja) | 2006-11-24 | 2012-09-19 | 有限会社ノーベル医学研究所 | ドライマウスおよび/または唾液分泌障害を処置するための医薬 |
WO2008119032A1 (en) | 2007-03-27 | 2008-10-02 | Perscitus Biosciences, Llc | Compositions and methods for protecting cells from toxic exposures |
CN101795701A (zh) | 2007-05-14 | 2010-08-04 | 纽尔雅制药公司 | 用于治疗神经元代谢减退的乙酰coa羧化酶抑制剂 |
WO2009023357A2 (en) | 2007-05-25 | 2009-02-19 | University Of Rochester | Curcumin derivatives and their use as radioprotectors |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
ES2655367T3 (es) | 2008-08-21 | 2018-02-19 | Oxford University Innovation Limited | Bebida que comprende éster de hidroxibutirato y uso médico de la misma |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
CA2760410A1 (en) | 2009-04-16 | 2010-10-21 | Isis Innovation Limited | Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
FR2958154B1 (fr) | 2010-04-01 | 2012-06-08 | Oreal | Procede de soin et/ou de maquillage des rides |
KR20140008394A (ko) | 2011-02-17 | 2014-01-21 | 시에이치디 바이오사이언스 인코포레이티드 | 퍼옥시 α-케토카르복실산을 포함하는 조성물 및 이를 생산하고 사용하기 위한 방법 |
WO2012113415A1 (en) | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
EP2914251B1 (en) | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
EP2984066B1 (en) | 2013-03-14 | 2017-02-01 | Oxford University Innovation Limited | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
GB201314127D0 (en) | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
-
2009
- 2009-01-05 TR TR2019/08522T patent/TR201908522T4/tr unknown
- 2009-01-05 WO PCT/US2009/030095 patent/WO2009089144A1/en active Application Filing
- 2009-01-05 CN CN201610322704.XA patent/CN106038532B/zh active Active
- 2009-01-05 EP EP09701051.6A patent/EP2240017B1/en active Active
- 2009-01-05 US US12/811,648 patent/US9211275B2/en active Active
- 2009-01-05 AU AU2009204370A patent/AU2009204370B2/en active Active
- 2009-01-05 DK DK09701051.6T patent/DK2240017T3/da active
- 2009-01-05 CN CN2009801049582A patent/CN101969769A/zh active Pending
- 2009-01-05 ES ES09701051T patent/ES2730879T3/es active Active
-
2015
- 2015-11-03 US US14/931,265 patent/US10154982B2/en active Active
-
2018
- 2018-11-29 US US16/203,748 patent/US11311509B2/en active Active
-
2022
- 2022-04-25 US US17/728,600 patent/US20230075547A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106038532B (zh) | 2019-05-14 |
EP2240017B1 (en) | 2019-03-13 |
US10154982B2 (en) | 2018-12-18 |
CN106038532A (zh) | 2016-10-26 |
US20230075547A1 (en) | 2023-03-09 |
US20100298294A1 (en) | 2010-11-25 |
US11311509B2 (en) | 2022-04-26 |
AU2009204370B2 (en) | 2014-12-04 |
WO2009089144A1 (en) | 2009-07-16 |
ES2730879T3 (es) | 2019-11-13 |
US9211275B2 (en) | 2015-12-15 |
EP2240017A1 (en) | 2010-10-20 |
US20160193173A1 (en) | 2016-07-07 |
EP2240017A4 (en) | 2011-02-16 |
AU2009204370A1 (en) | 2009-07-16 |
US20190201366A1 (en) | 2019-07-04 |
DK2240017T3 (da) | 2019-06-17 |
CN101969769A (zh) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201908522T4 (tr) | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. | |
Gura et al. | Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition | |
SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
MX2011007544A (es) | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. | |
WO2003022288A1 (fr) | Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
ZA200909230B (en) | Improving memory in subjects with mini-mental state examination of 24-26 | |
MY150595A (en) | Nutritional composition to promote healthy development and growth | |
MX2007006707A (es) | Acidos grasos omega-3 y agente dislipidemico para terapia lipidica. | |
ES2571856T3 (es) | Uso de composiciones nutricionales para prevenir la adiposidad visceral | |
NZ608292A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
MY167583A (en) | Infant formula with high sn-2 palmitate and oligofructose | |
WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
BRPI0716108B8 (pt) | composição, uso de uma composição, e, método para fabricação de uma composição | |
WO2007038641A3 (en) | Methods and therapies for treating inflammatory conditions with exposed collagen | |
HK1129071A1 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
WO2007005774A3 (en) | Novel derivatives of amino acids for treatment of obesity and related disorders | |
WO2006102643A3 (en) | Stably transformed bone marrow-derived cells and uses thereof | |
US9987243B2 (en) | Use of trans-palmitoleate in identifying and treating metabolic disease | |
AR046454A1 (es) | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica | |
TR200704897A1 (tr) | Uzatılmış salım sağlayan gliklazid formülasyonları@ | |
Miyauchi et al. | Urinary tract infection as a cause of hyperammonemic encephalopathy | |
US20130029996A1 (en) | Special composition for the use thereof as a drug | |
JP5734134B2 (ja) | 抗疲労用医薬組成物 | |
Lu et al. | Antibacterial effects of platelet-rich plasma in promoting facial scars healing in combination with adipose-derived stromal vascular fraction cells |